Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04478630 · ClinicalTrials.gov registry record · NA

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

A NA study, sponsored by Milton S. Hershey Medical Center.

Terminated
Registry status
NA
Development phase
12
Enrollment target

NCT04478630: Clinical Trial NA study, sponsored by Milton S. Hershey Medical Center.

NCT04478630 is a NA study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04478630, a NA study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.

TERMINATED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This study is a three group, randomized, double blind, placebo-controlled trial with two repeated measurements. The same measurements will be collected for each participant during two consecutive chemotherapy treatment cycles.Subjects will be provided with written instructions as an educational handout as well as essential oil safety information. Subjects will be able to demonstrate an ability and accurate understanding of the proper use of the diffusers, using a demonstration diffuser, at the time of consent. At the time the subject will provide written informed consent, they will be randomly assigned to one of the three groups with a pocket diffuser containing either ginger essential oil, peppermint essential oil, or vanilla extract )placebo- control). This is based on a pre-determined list of random assignments. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). In addition to the Pre-treatment Assessment, occurring before each of the 2 cycles of chemotherapy, the subjects will be contacted to complete assessments at approximately 24 and 72 hours post-chemotherapy. A member of the study team will call the participant again at their preferred time of day to ask the survey questions. The same procedures will be repeated during the participant's second cycle of chemotherapy, which is likely two or three weeks after the first one.

Primary Outcome

N\&V experienced during the first 24 hours after chemotherapy administration as measured by the Memorial Symptom Assessment Scale's nausea and vomiting dimension with values for symptoms, if experienced, on a 4-point scale; its frequency, if appropriate, on a 4-point scale; and its associated distress on a 5-point categorical scale. The higher the score determines a worse outcome in all areas.

Interventions

  • OTHER Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-08-30
Est. Completion 2023-02-18
Phase NA
Milton S. Hershey Medical Center

396 total trials

Why NCT04478630 stopped before completion

NCT04478630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract is the first listed.

NCT04478630 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04478630 about?

NCT04478630 is a clinical study titled "The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting". This study is a three group, randomized, double blind, placebo-controlled trial with two repeated measurements. The same measurements will be collected for each participant during two consecutive chemotherapy treatment cycles.Subjects will be provided with written instructions as an educational hand...

What is the current status of trial NCT04478630?

This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2021-08-30. Estimated completion is 2023-02-18.

What interventions are being tested in trial NCT04478630?

The interventions under investigation include: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (OTHER).

Who is sponsoring clinical trial NCT04478630?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04478630's enrollment target sits among peer trials

12 1913th of 2000 higher than 74 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04478630, the US trial registry maintained by the National Library of Medicine. NCT04478630 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.